Skip to Content

CYCLONE 2: Abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer

Abemaciclib is an oral selective inhibitor of CDK4&6, that is FDA-approved to treat patients suffering from HR+, HER2- metastatic breast cancer. Recent preclinical studies on prostate cancer cell lines and xenograft models indicate that abemaciclib induces cell cycle arrest and tumor growth inhibition. In this MEDtalk, Redas Trepiakas, MD, presents the results of CYCLONE 2, a randomized, placebo-controlled study investigating the effects of treating metastatic castration-resistant prostate cancer with abiraterone plus prednisone with or without abemaciclib.

Redas Trepiakas

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top